ACXP Acurx Pharmaceuticals, Inc.

86

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price
$3.5
Decreased by -0.28%
Dollar Volume
165.02 K
ADR%
8.6
Earnings Report Date (estimate)
Nov 14, 22 (-0.25)
Market Cap.
40.57 M
Shares Float
8.07 M
Shares Outstanding
11.59 M
Beta
0.00
Price / Earnings
-2.35
BPR
213.01
20D Range
3.46 4.58
50D Range
2.81 4.58
200D Range
2.33 4.85
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.32 -0.28
Decreased by -14.29%
Nov 10, 22 -0.32 -0.28
Decreased by -14.29%
May 10, 22 -0.26 -0.33
Increased by +21.21%
Mar 16, 22 -0.22 -0.40
Increased by +45.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
 -3.54 M
Increased by +11.55%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -2.62 M
Decreased by -139.75%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -2.67 M
Decreased by -192.34%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00 - -7.83 M -
Decreased by N/A%
-
Jun 30, 21 0.00 - -4.00 M -
Decreased by N/A%
-
Dec 31, 20 0.00 - -1.09 M -
Decreased by N/A%
-
Jun 30, 20 0.00 - -913.36 K -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.